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Abstract
Objective
Dynamic regulation of actin cytoskeleton is at the heart of all actin-based cellular events. In
this study, we sought to identify novel post-translational modifications of Profilin-1 (Pfn1), an
important regulator of actin polymerization in cells.
Methodology
We performed in vitro protein kinase assay followed by mass-spectrometry to identify Pro-
tein Kinase A (PKA) phosphorylation sites of Pfn1. By two-dimensional gel electrophoresis
(2D-GE) analysis, we further examined the changes in the isoelectric profile of ectopically
expressed Pfn1 in HEK-293 cells in response to forskolin (FSK), an activator of cAMP/PKA
pathway. Finally, we combined molecular dynamics simulations (MDS), GST pull-down
assay and F-actin analyses of mammalian cells expressing site-specific phosphomimetic
variants of Pfn1 to predict the potential consequences of phosphorylation of Pfn1.
Results and Significance
We identified several PKA phosphorylation sites of Pfn1 including Threonine 89 (T89), a
novel site. Consistent with PKA’s ability to phosphorylate Pfn1 in vitro, FSK stimulation
increased the pool of the most negatively charged form of Pfn1 in HEK-293 cells which can
be attenuated by PKA inhibitor H89. MDS predicted that T89 phosphorylation destabilizes
an intramolecular interaction of Pfn1, potentially increasing its affinity for actin. The T89D
phosphomimetic mutation of Pfn1 elicits several changes that are hallmarks of proteins
folded into alternative three-dimensional conformations including detergent insolubility, pro-
tein aggregation and accelerated proteolysis, suggesting that T89 is a structurally important
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residue of Pfn1. Expression of T89D-Pfn1 induces actin:T89D-Pfn1 co-clusters and dramat-
ically reduces overall actin polymerization in cells, indicating an actin-sequestering action of
T89D-Pfn1. Finally, rendering T89 non-phosphorylatable causes a positive charge shift in
the isoelectric profile of Pfn1 in a 2D gel electrophoresis analysis of cell extracts, a finding
that is consistent with phosphorylation of a certain pool of intracellular Pfn1 on the T89 resi-
due. In summary, we propose that T89 phosphorylation could have major functional conse-
quences on Pfn1. This study paves the way for further investigation of the potential role of
Pfn1 phosphorylation in PKA-mediated regulation of actin-dependent biological processes.
Introduction
Actin-based cell migration is fundamental to a number of physiological processes including,
but not limited to, embryonic development, wound healing and inflammatory response. Cell
migration correlates with marked changes in the actin cytoskeleton where a motile cell has
extremely rapid and directed actin polymerization and turnover [1]. Membrane protrusion of
the leading edge is the initiating event of cell migration and requires de novo actin nucleation
followed by filament elongation and/or elongation of pre-existing filaments, catalyzed by vari-
ous nucleation-promoting and elongating factors (e.g. N-WASP/WAVE, formins and Ena/
VASP). These factors harbor poly-L-proline (PLP) domains through which they interact with
profilins (Pfn), a family of actin-monomer binding proteins that strongly inhibits spontaneous
nucleation and elongation at the pointed ends of actin filaments but promotes barbed-end
elongation through the addition of ATP-bound monomeric actin [2]. Interaction with Pfn1
(the most abundant isoform of Pfn in mammals) enhances the actin polymerizing abilities of
nucleation-promoting and elongating factors in vitro and in vivo [3–6].
How Pfn1’s interactions with its ligands are regulated in cells is still not clearly understood.
At least three types of regulatory mechanisms have been proposed in the literature. First, based
on findings that Pfn1 exhibits affinity for membrane phosphoinositides (PPI), and PI(4,5)P2
(the most abundant PPI species in cells) micelles can dissociate the Pfn1:actin complex, it has
been speculated that phospholipase C-mediated PI(4,5)P2 hydrolysis could trigger the release
of Pfn1 from the plasma membrane enabling its interaction with actin [7]. Whether this actu-
ally occurs in cells has not been examined yet. Second, it was shown that when treated with per-
oxynitrile, Pfn1 becomes nitrated on a single tyrosine residue at the C-terminus, and this type
of modification increases and decreases Pfn1’s affinities for PLP ligands and actin, respectively
[8]. It was further demonstrated that activation of inducible Nitric Oxide synthase results in
Pfn1 nitration in platelets [9]. Therefore, nitric oxide signaling could potentially modulate
ligand interactions of Pfn1. Third, there is also evidence that Pfn1 can be phosphorylated on
tyrosine and serine residues. For example, in endothelial cells, VEGFR2 activation leads to Src-
mediated phosphorylation of Pfn1 on residue Y129 which increases its affinity for actin [10].
Similarly, activation of the Rho pathway causes ROCK (Rho-associated coiled-coiled kinase)-
mediated phosphorylation of Pfn1 on residue S137 [11] impacting its binding to PLP ligands
(note that phosphorylation at this site can be also mediated by PKC at least in vitro [12]).
These studies suggest that acute activation of certain signaling pathways can modulate ligand
interactions of Pfn1 through phosphorylation.
The overall goal of this study was to identify other novel phosphorylation events of Pfn1
that can have important functional consequences. We here report that PKA can directly phos-
phorylate Pfn1 at multiple residues including T89, a residue that is involved in its interaction
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with actin. Consistent with molecular dynamics simulations, expression studies of phosphomi-
metic variant of Pfn1 further suggest that T89 is a structurally important residue, phosphoryla-
tion of which is likely to influence actin-binding of Pfn1.
Materials and Methods
Cell culture
HEK-293 cells (ATCC, CRL-1573) were cultured in DMEM/F12 (1:1) (Life Technologies,
Carlsbad, PA, USA) growth medium [10% (v/v) FBS, 100U/mL penicillin, 100μg/mL strepto-
mycin]. HEK-293 cells were maintained on culture dishes (Corning, Corning, NY, USA)
coated with type I collagen (BD Biosciences, Franklin Lakes, NJ, USA) for all experiments.
MDA-MB-231 cells (ATCC, HTB-26) were cultured in EMEM (Lonza; Basel, Switzerland)
growth medium [10% (v/v) FBS, 100U/ml penicillin, 100μg/ml streptomycin]. For activation of
cAMP/PKA pathway, cells were serum-starved for 6 hours prior to treatment with 50μM FSK
(Sigma, St. Louis, MO) for 5–10 min. In some experiments, cells were pretreated with 10μM
H89 (Sigma) or DMSO (vehicle control) for 15 min prior to changing to FSK-containing
media in the continued presence of H89 (or DMSO).
Plasmids and transfection
Phosphomimetic (S57D, T89D, S91D, T92D) and phosphodead (T89A) mutations ofMus
musculus Pfn1 were introduced into either a bacterial expression vector encoding GST-Pfn1 (a
generous gift from Dr. Gerard Marriott, UC Berkeley) or a bicistronic mammalian expression
vector (pIRES2-AcGFP1—Clontech, Mountain View, CA, USA) encoding myc-Pfn1 (cloning
sites—Xho1, BamH1) using the primers summarized in S1 Table. Plasmid DNA transfections
for HEK-293 and MDA-231 cells were performed using XtremeGENE HP transfection reagent
(Roche, Basel, Switzerland) and Lipofectamine LTX Plus (Life Technologies, Carlsbad, PA,
USA), respectively, according to the manufacturer’s instructions. Gene silencing of Pfn1 was
performed as described previously [13]. Pfn1 plasmids were rendered siRNA-resistant by
introducing two base-pair silent mutations in the Pfn1-siRNA targeting region.
In vitro Kinase assay
His-tagged Pfn1 (1.5 μg; Cytoskeleton Inc, Denver, CO) was added to kinase buffer [20mM
BES (Sigma) pH 7, 20mM EGTA (Fisher Scientific, Waltham, MA), 6mMMgCl2 (Fisher Sci-
entific), 5mM ATP (Sigma), 10mM phosphocreatine (Sigma), 1mM DTT (Roche, Basel, Swit-
zerland)] and incubated with or without 0.5U/μL catalytic subunit of bovine PKA (Sigma) at
30°C for 1 hour with gentle mixing every 15 minutes. The reaction was stopped by boiling the
products for 5 minutes in the presence of 2-mercaptoethanol. Reaction products were run on
SDS-PAGE and visualized by silver staining.
In gel trypsin digestion
In gel trypsin digestion was carried out as previously described [14]. PKA treated His-tagged
Pfn1 was first subjected to SDS-PAGE. The gels were washed twice with MilliQ water for 5
minutes each and then stained with Coomassie blue [0.1% (w/v) R250 (Fisher Scientific, Wal-
tham, MA, USA), 40% (v/v) ethanol (Decon, King of Prussia, PA, USA), 10% (v/v) Acetic Acid
(Fisher Scientific, Waltham, MA, USA)]. After destaining gels with a destaining solution [10%
(v/v) ethanol, 7.5% (v/v) acetic acid], His-tagged Pfn1 gel band was excised, washed with
HPLC water and destained with 50% acetonitrile (ACN)/25mM ammonium bicarbonate until
staining was no longer visible. Gel pieces were dehydrated with 100% ACN, reduced with
T89 Phosphorylation of Profilin-1
PLOS ONE | DOI:10.1371/journal.pone.0156313 May 26, 2016 3 / 20
10mM dithiothreitol (DTT) at 56°C for 1 hour, followed by alkylation with 55mM iodoaceta-
mide (IAA) at room temperature for 45 min in the dark. Gel pieces were then again dehydrated
with 100% ACN to remove excess DTT and IAA, and rehydrated with 20ng/μl trypsin/25mM
ammonium bicarbonate and digested overnight at 37°C. The resultant tryptic peptides were
extracted with 70% ACN/5% formic acid, vacuum dried and reconstituted in 18μl 0.1% formic
acid.
Tandemmass spectrometry analysis
Proteolytic peptides from in gel trypsin digestion were analyzed by a nanoflow reverse-phased
liquid chromatography tandem mass spectrometry (LC-MS/MS). Tryptic peptides were loaded
onto a C18 column (PicoChip™ column packed with 10.5cm Reprosil C18 3μm 120Å chroma-
tography media with a 75μm ID column and a 15μm tip, New Objective, Inc., Woburn, MA,
USA) using a Dionex HPLC system (Dionex Ultimate 3000, ThermoFisher Scientific, Wal-
tham, MA, USA) operated with a double-split system (Personal communication with Dr. Steve
Gygi from Department of Cell Biology, Harvard Medical School) to provide an in-column
nano-flow rate (~300 nl/min). Mobile phases used were 0.1% formic acid for A and 0.1% for-
mic acid in acetonitrile for B. Peptides were eluted off the column using a 52 minute gradient
(2–40% B in 42 min, 40–95% B in 1 min, 95% B for 1 min, 2% B for 8 min) and injected into a
linear ion trap MS (LTQ-XL, ThermoFisher Scientific, Waltham, MA, USA) through electro-
spray. The LTQ XL was operated in a date-dependent MS/MS mode in which each full MS
spectrum [acquired at 30000 automatic gain control (AGC) target, 50ms maximum ion accu-
mulation time, precursor ion selection range of m/z 300 to 1800] was followed by MS/MS
scans of the 5 most abundant molecular ions determined from full MS scan (acquired based on
the setting of 1000 signal threshold, 10000 AGC target, 100ms maximum accumulation time,
2.0Da isolation width, 30ms activation time and 35% normalized collision energy). Dynamic
exclusion was enabled to minimize redundant selection of peptides previously selected for
CID. The MS raw files have been deposited to Chorus (https://chorusproject.org/pages/index.
html) under the project “Phosphorylation of Pfn1”.
Peptide identification by database search
MS/MS spectra were searched using the SEQUEST search engine implemented in Proteome
Discoverer™ software (v. 1.4.0, ThermoFisher Scientific, Waltham, MA, USA) against a UniProt
human proteome database (January 2013 release) from the European Bioinformatics Institute
(http://www.ebi.ac.uk/integr8). The following modifications were used: static modification of
cysteine (carboxyamidomethylation, +57.05 Da), variable modification of methionine (oxida-
tion, +15.99Da) and variable modification of serine/threonine/tyrosine (phosphorylation,
+79.97Da). The mass tolerance was set at 1.4Da for the precursor ions and 0.5Da for the frag-
ment ions. Peptide identifications were filtered using PeptideProphet™ and ProteinProphet1
algorithms with a protein threshold cutoff of 99% and peptide threshold cutoff of 95% imple-
mented in Scaffold™ (Proteome Software, Portland, Oregon, USA).
Two-dimensional gel electrophoresis (2D-GE)
Cells were scraped in the presence of 2D lysis buffer [2M urea (Fisher Scientific), 7M thiourea
(Life Technologies, Carlsbad, PA, USA), 4% (w/v) CHAPS (Sigma), 50mM DTT] and collected
into a bead-beater tube (Biospec, Bartlesville, OK, USA) containing 50mg Glass Beads (Sigma).
Isoelectric focusing was performed using the Zoom IPG Runner System (Life Technologies)
according to manufacturer’s instructions with modification. Briefly, lysates were reconstituted
in rehydration buffer [final concentrations: 2M urea, 7M thiourea, 4% (w/v) CHAPS, 50mM
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DTT, 0.5% (v/v) carrier ampholytes (Life Technologies), 0.005% (w/v) bromophenol blue
(Fisher Scientific), 50–150μg protein]. IPG strips underwent isoelectric focusing using the fol-
lowing program: 175V for 45 minutes; linear ramp 175-2000V over 45 minutes; 2000V for 45
minutes. IPG strips were briefly washed with running buffer [25mM Tris (pH 8.3), 192mM
glycine, 0.1% (w/v) SDS] and sealed on Tris-HCl polyacrylamide gels with running buffer con-
taining 0.5% agarose (Life Technologies) and 0.005% (w/v) bromophenol blue before perform-
ing electrophoresis in the second dimension followed by immunoblotting.
Immunoblotting
Total lysates were prepared by extracting cells with modified RIPA buffer (25mM Tris—HCl
(pH 7.5), 150mMNaCl, 1% (v/v) NP-40, 5% (v/v) glycerol, 1mM EDTA, 50mMNaF, 1mM
sodium pervanadate, and protease inhibitors). In some experiments, SDS and/or urea were
added to RIPA buffer at final concentrations of 2% and 6M, respectively. Immunoblotting con-
ditions for the various antibodies were: monoclonal GFP (Clontech, Mountain View, CA, USA,
1:3000), monoclonal Pfn1 (Abcam, Cambridge, England, 1:3000), monoclonal actin (BD Bio-
sciences, Frankin Lakes, NJ, USA. 1:1000), monoclonal myc (Sigma, 1:3000), monoclonal α-
tubulin (Sigma, 1:3000), monoclonal VASP (BD Biosciences, Frankin Lakes, NJ, USA, 1:1000)
and monoclonal p27kip1 (BD Biosciences, Franklin Lakes, NJ, USA, 1:2000).
Phalloidin staining—Cells were washed with DPBS, fixed with 3.7% formaldehyde for 15
min, permeabilized with 0.5% Triton X-100 for 5 min and then blocked with 10% goat-serum
for 1 h at room temperature. Cells were incubated with rhodamine-phalloidin (Life Technolo-
gies) for an hour at room temperature. Stained cells were washed two times with PBS contain-
ing 0.02% tween, two times with PBS, and then once with distilled water before mounting on
slides for imaging using a 60X oil-immersion objective on an Olympus IX71 inverted
microscope.
GST-pull down assay
Bacteria carrying various forms of GST-Pfn1 were grown at 37°C under constant agitation in
the presence of antibiotics until the optical density at 600 nm was between 0.6 and 0.9. Cells
were induced with 0.1mM isopropyl-β-D- thiogalactopyranoside (IPTG) for 3 hours, and
extracted with lysis buffer (25mM Tris-base (pH 7.4), 150mMNaCl, 1% NP-40, 1mM EDTA,
5% glycerol) followed by sonication. Bacterial extracts were clarified at 18000g for 30 minutes
before incubating with glutathione-agarose beads (Sigma) for 2 hours at 4°C with constant
rotation. Beads were washed 5 times with lysis buffer and subjected to pull-down assay with
HEK-293 lysate overnight at 4°C. After washing the beads 5 times with lysis buffer, protein was
eluted by boiling beads for 5 minutes in the presence of 2-mercaptoethanol and subjected to
SDS-PAGE and immunoblot analyses.
Molecular Dynamics Simulation
A homology model ofMus musculus Pfn1 was created from a crystal structure of bovine Pfn1
bound to actin (PDB 2BTF). The model was created by manually performing the following
mutations using Pymol: N9S, N41S, I49V, I100V, and M122L. All mutations could be per-
formed without introducing significant steric clashes. Additional Pfn1 models were created by
mutating T89 to either alanine or aspartic acid to mimic phospho-dead and phosphorylated
states as well as to phosphothreonine. All simulations were performed with GPU accelerated
Amber version 14 with the ff14sb force field [15]. Parameters for phosphothreonine were
taken from a previously published study [16]. The homology modules were solvated to form an
octahedral TIP3P water box that extends 12 Å beyond the protein. The system was neutralized
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with Na+ or Cl- ions as needed. The system then underwent two rounds of minimization. A
100ps constant volume run was performed with weak positional restraints on the protein dur-
ing which the temperature was warmed from 0°K to 300°K followed by an unrestrained con-
stant temperature and pressure equilibration run of 100pS. Simulations were performed using
the particle mesh Ewald (PME) method with a non-bonded cutoff of 10Å. Constant pressure
periodic boundaries and isotropic position scaling were used to maintain a pressure of 1 atm.
Langevin dynamics were used for temperature control. Three separate simulations of each
model were run with different random seeds and every simulation was run for 300ns, resulting
in 900ns of simulation per a model. Analysis of the simulations was performed using MDAna-
lysis [17].
Statistics
We performed either Student’s t-test or one-way ANOVA (when more than two groups were
involved) for statistical comparison of the means between the different groups and p<0.05 was
considered to be statistically significant.
Results
PKA phosphorylates Pfn1 on multiple residues in vitro
To predict potential phosphorylation sites of Pfn1and the likely kinases associated with these
sites, we performed sequence analyses of both human and mouse Pfn1 using two different bio-
informatics tools (NetphosK, KinasePhos), the results of which are summarized in S2 Table.
As per these analyses, the abundance of predicted phosphorylation sites is higher for serine/
threonine residues than tyrosine residues, and among the various candidate serine-threonine
kinases considered, PKA and PKC, the two AGC-family kinases, are associated with the most
number of predicted phosphorylation sites. PKC-mediated phosphorylation of Pfn1 on S137
residue has been characterized previously [11,12]. Based on alterations in post-translational
modification patterns of Pfn isoforms in astrocytes upon treatment with FSK (an activator of
cyclic AMP-PKA pathway), it has been recently suggested that PKA may be involved in post-
translational regulation of Pfn isoforms [18]. Whether Pfn1 is a phosphorylation substrate of
PKA however remains unknown. Therefore, as a potential strategy to uncover novel phosphor-
ylation sites of Pfn1, we performed in vitro phosphorylation assays using recombinant His-
tagged Pfn1 and the catalytic subunit of PKA. We observed acidic shift of a significant popula-
tion of His-Pfn1 (unmodified isoelectric point ~6.5) as evident from several new charged states
demonstrating that PKA is capable of directly phosphorylating Pfn1 at multiple residues at
least in vitro (Fig 1A). To identify these phosphorylation sites of Pfn1, PKA-treated His-Pfn1
was trypsin-digested and subjected to LC-MS/MS analysis. A number of Pfn1 peptides cover-
ing 53% of Pfn1 sequences were identified, including three singly phosphorylated peptides.
Fragmentation patterns of these phosphopeptides were able to narrow down the potential
phosphorylation sites to 3 serine/threonine residues: S56/S57, T89, S91/T92 (Fig 1B). Note that
the MS/MS spectra are not able to locate the exact modification sites for some phosphopeptides
due to the presence of multiple serine/threonine residues (e.g. S56/S57 and S91/T92) and the
absence of signature fragment ions for site specificity. Multiple sequence alignment of Pfn1 in
vertebrates revealed a high degree of conservation of S56, S57, T89, S91, T92 and the surround-
ing residues (data not shown). As the protein coverage was incomplete, we could not rule out
the possibility of other PKA-phosphorylation sites of Pfn1.
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Fig 1. Pfn1 can be phosphorylated by PKA onmultiple residues. A) His-tagged Pfn1 was treated with
buffer containing ATP with or without PKA followed by 2D electrophoresis and visualized by silver staining
(isoelectric focusing was conducted using a pH 4–7 IPG strip). Phosphorylation spots are marked by arrows.
B)Mass-spectrometry based detection of phosphopeptides from PKA-treated His-Pfn1 reveled Pfn1
phosphorylation on three residues (S56/S57, T89, and S91/T92).
doi:10.1371/journal.pone.0156313.g001
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Activation of cAMP/PKA pathway induces acidic charge shift of Pfn1 in
non-neuronal cells
Next, to determine whether activation of cAMP-PKA pathway has any effect on the isoelectric
profile of Pfn1 in non-neuronal cells, HEK-293 cells overexpressing myc-Pfn1 were either
serum-starved or acutely stimulated by FSK before performing 2D-GE analyses of cell extracts.
We chose to investigate FSK’s effect on isoelectric profile of myc-Pfn1 instead of endogenous
Pfn1 for two main reasons. First, we reasoned that small changes in the isoelectric profile
would be easier to detect in an overexpressed condition. Second, our pilot experiments demon-
strated that myc-Pfn1 (theoretical PI: 6.3) is much better resolvable than endogenous Pfn1
(theoretical PI—8.3) on IEF, likely owing to its acidic nature (it circumvents the problem of
reducing agent DTT migrating away the protein). We found that even under serum-starved
condition, myc-Pfn1 exists in multiple charged states as evident from three distinct spots
(spots #1 through 3) with spot #2 representing the predominant pool of myc-Pfn1 and an
extremely weak fourth spot (#4) representing the most negatively charged form of the protein
(Fig 2A). The most obvious FSK-dependent change in the 2D profile of myc-Pfn1 was a promi-
nent increase in the intensity of spot #4 (Fig 2A) reflecting an acidic charge shift involving a
small pool of Pfn1, a finding that is consistent with PKA’s ability to phosphorylate Pfn1 in
vitro. As spot #2 accounted for>95% of total pool of myc-Pfn1, we used the relative intensities
of spot #2 at a very low exposure (that does not saturate the signal of this spot) between control
and FSK-treatment groups as a correction factor for loading control in these experiments to
quantify the fold-changes in the intensity of spot #4 in response to FSK. Using this correction
factor, we estimated that FSK treatment led to approximately 9-fold (data summarized from 4
independent experiments) increase in the intensity of spot #4 (Fig 2B). In a set of follow-up
experiments, we examined the isoelectric profile of myc-Pfn1 in FSK-stimulated HEK-293 cells
with or without pharmacological inhibition of PKA by H89. As expected, H89 pretreatment
significantly reduced the intensity of spot #4 (Fig 2C and 2D) further confirming that the most
negatively charged pool of Pfn1 in FSK-treated condition is PKA-dependent. Overall, these
cell-based experimental results are in agreement with PKA’s effect on Pfn1 in vitro.
T89 phosphorylation affects the biochemical characteristics of Pfn1
Phosphopeptides of Pfn1 involving S56, S57, T89, S91, T92 have been previously found in
global proteomic screens of mitotic cells, cancer and immortalized T cell lines, and endothelial
cells suggesting that Pfn1 can be phosphorylated on these residues at least in some cell types
under certain conditions [10,19,20]. However, the functional significances of these post-trans-
lational modifications of Pfn1 are not known. We were particularly interested in the functional
consequence of T89 phosphorylation since in a bound conformation with actin (PDB 2BTF),
the backbone oxygen of T89 of Pfn1 makes an intermolecular hydrogen bond with Y166 of
actin (Fig 3A and 3B) making T89 as a potentially interesting site for further exploration of
possible regulation of the Pfn1:actin interaction. In the monomeric, unbound (i.e when not
interacting with any other ligand) structure of Pfn1 (PDB 1PFL), the backbone oxygen of T89
forms an intramolecular hydrogen bond interaction (distance 3.0 Å) with the backbone
nitrogen of F98 (Fig 3C). The T89:F98 hydrogen bond marks the transition between the loop
defined by residues 89–98 and a beta sheet. Due to the geometry of the interactions, the intra-
molecular T89 (Pfn1):F98 (Pfn1) and intermolecular T89 (Pfn1):Y166 (actin) hydrogen bonds
are mutually exclusive. Given the importance of the intramolecular T89:F98 interaction of
Pfn1 in determining its interaction with actin, we asked whether phosphorylation of T89 could
potentially affect the 98N-89O hydrogen bond. To address this question, we performed molec-
ular dynamics simulations (MDS) on monomeric homology models of wild-type (WT)-Pfn1
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with or without phosphorylated-T89, T89D-Pfn1 (T89 was replaced by an aspartic acid, a strat-
egy that is commonly used to artificially mimic a phosphorylated state of an amino acid) or
T89A (T89 was replaced by an alanine to simulate a corresponding non-phosphorylatable ver-
sion). All simulations were started with a conformation where T89:F98 interaction was not ini-
tially formed. We assessed the stability of the intramolecular 98N-89O hydrogen bond over the
course of three independent 300-ns simulations. The time-dependent fluctuation of 98N-89O
distance for each of the three simulations and a histogram summarizing the results of all
three simulations for the four variants (WT, WT-phosphoT89, T89A and T89D) of Pfn1 are
depicted in Fig 4. In all three simulations, the WT protein quickly established a stable intramo-
lecular T89:F98 (distance 3.0 Å) bond. By contrast, the intramolecular hydrogen bond was
not formed in any of the three THP89 (phosphorylated T89) simulations, suggesting that phos-
phorylation of T89 causes an extreme destabilization of the intramolecular T89:F98 interaction.
Even though the histogram pattern of the T89D simulation was not exactly identical to that
of THP89, in two out of three simulations T89D-Pfn1 also completely failed to establish
the hydrogen bond throughout the course of the simulation suggesting that T89D-Pfn1 is a
Fig 2. Pfn1 can be post-translationally modified in a PKA-dependent manner in HEK-293 cells. A)
Lysates prepared frommyc-Pfn1-expressing HEK-293 cells were resolved on 4–7 pH gradient IEF gels and
then immunoblotted with anti-myc antibody to reveal the isoelectric profile of myc-Pfn1 in serum-starved
(control: S-) vs FSK-stimulated conditions—two different exposure blots are shown.B) A bar graph
summarizing the relative average intensity of the spot representing the most negatively charged form of myc-
Pfn1 (spot #4) in control vs FSK-stimulated conditions.C-D) Isoelectric profiles of myc-Pfn1 in FSK-
stimulated cells with or without H89 treatment (panel C), and the corresponding quantifications of the intensity
of spot #4 (panel D). N denotes the number of independent experiments (*: p<0.05).
doi:10.1371/journal.pone.0156313.g002
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reasonable mimic for T89-phosphorylated Pfn1. Similarly, the histogram pattern of the T89A
mutant, although not identical, was also fairly similar to that of the WT protein suggesting that
this non-phosphorylatable mutant also stabilizes the interaction. The differences in histogram
patterns between T89A andWT or THP89 and T89D simulations were not totally unexpected
since aspartic acid and alanine are not structurally identical to phosphorylated and unpho-
sphorylated threonine, respectively. In summary, these simulation results predicted that the
intramolecular T89:F98 interaction of Pfn1 could be sensitive to the phosphorylation status of
T89. Since T89 (Pfn1):F98 (Pfn1) and T89 (Pfn1):Y166 (actin) interactions are mutually exclu-
sive, one possible consequence of destabilization of the T89:F98 interaction upon T89 phos-
phorylation is enhanced stability of the T89 (Pfn1):Y166 (actin) interaction when Pfn1 is in a
complex with actin and, therefore, a potential stronger affinity of Pfn1 for actin.
We next performed GST-pull-down assays of bacterially expressed forms of either WT
(control)- or various phosphomimetic Pfn1 using HEK-293 cell lysate to qualitatively assess
the changes in Pfn1:actin binding conferred by T89D substitution. To our surprise, the pull-
down assay failed for T89D-Pfn1 as this mutant protein was largely insoluble in non-denatur-
ing lysis buffer and therefore could not be extracted from the bacteria (Fig 5A). T89D-Pfn1
was extractable from bacteria only under denaturing lysis buffer and in the presence of urea
(Fig 5B), a condition that is unfortunately non-permissive for binding studies. The protein
Fig 3. Molecular interactions of T89 of Pfn1. A) Actin-interacting surface of Pfn1 (Pfn1: blue; actin: grey);
phosphorylatable residues of Pfn1 are indicated as sticks.B) In unbound Pfn1 (PDB 1PFL) T89 forms an
intramolecular hydrogen bond with F98. C) In the Pfn1-actin complex (PDB 2BTF) an intermolecular
hydrogen bond (dashed yellow line) is observed between T89 of Pfn1 (blue) and Y166 of actin (green).
doi:10.1371/journal.pone.0156313.g003
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insolubility issue was specific to T89D substitution since phosphomimetic Pfn1 constructs
involving all other PKA sites (S57, S91 and T92) were extractable in non-denaturing lysis buffer
and showed ability to bind actin and VASP (a PLP ligand of Pfn1) similar to the extent of WT
Pfn1, at least, on a qualitative scale (Fig 5A). Even in mammalian HEK-293 cells, T89D-Pfn1,
when transiently expressed as an EGFP-tagged protein, was barely extractable in non-denatur-
ing lysis buffer and could only be extracted efficiently when both SDS and urea were present in
the lysis buffer; WT- and T89A-Pfn1 were fully extractable in mild non-denaturing lysis buffer
as expected (Fig 5C). Similarly, T89D-Pfn1 was hardly extractable in non-denaturing lysis
buffer when expressed as a myc-tagged protein (S1 Fig). Therefore, protein insolubility of
T89D-Pfn1 does not appear to be either epitope-tag- or cell-type (bacterial vs mammalian)-
specific effect. Fluorescence microscopy of HEK-293 cells transfected with the various
EGFP-Pfn1 constructs revealed that nearly all cells expressing EGFP-T89D-Pfn1 formed
prominent protein aggregates of EGFP-Pfn1 whereas neither WT nor T89A overexpressors
demonstrate EGFP-Pfn1 clustering, a result that is consistent with the insolubility characteris-
tics of T89D-Pfn1 (Fig 5D). At the protein level, expression of EGFP-Pfn1-T89D was always
found to be much lower than either of the other two exogenous (WT or T89A) forms of Pfn1
Fig 4. Molecular Dynamics Simulation predicting the effect of T89 phosphorylation on the stability of
intramolecular 98N-89O bond. The stability of this intramolecular 98N-89O bond over the course of three 300ns
molecular dynamics simulations of monomeric Pfn1 are shown for homology models based on the bound structure for
WT, T89A, T89D and phosphorylated T89 (THP89) variants of Pfn1 (each color represents an individual simulation).
The histograms alongside the line graphs summarize the results of all three simulations for each variant of Pfn1.
doi:10.1371/journal.pone.0156313.g004
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Fig 5. Effect of site-specific phosphorylation on biochemical characteristics of Pfn1. A) Pull-down assays of
indicated GST-tagged Pfn1 constructs with HEK-293 cell lysate were run on an SDS-PAGE and immunoblotted with
anti-actin and anti-VASP antibodies (GST was used as a negative control). Coomassie stain in parallel confirms
comparable amounts of GST-tagged proteins in the pull-down assay. Note that virtually negligible amount of
T89D-Pfn1 was found to be immobilized on glutathione-linked agarose beads.B) Bacteria expressing indicated GST-
tagged Pfn1 constructs were lysed with either non-denaturing (containing 1% NP-40) or denaturing (containing 1% NP-
40, 2% SDS for one buffer and the other with 6M urea in addition) extraction buffers. Bacterial lysates were
immunoblotted with anti-Pfn1 antibody to demonstrate that T89D-Pfn1 is insoluble in non-denaturing lysis buffer.C)
HEK-293 cells expressing indicated EGFP-fused Pfn1 constructs were lysed with either non-denaturing (containing 1%
NP-40) or denaturing (containing 1% NP-40, 2% SDS for one buffer and the other with 6M urea in addition) extraction
buffers. HEK-293 lysates were immunoblotted with anti-GFP antibody to demonstrate that GFP-T89D-Pfn1 is also
insoluble in non-denaturing lysis buffer. Note that endogenous Pfn1 level is not affected by expression of any of the
ectopic Pfn1 constructs and extractable completely in non-denaturing lysis buffer. D) Fluorescence images of HEK-293
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(Fig 5C). This was not due to differences in the levels of transfected DNA since mRNA levels of
all three EGFP-fused Pfn1 constructs were comparable (S2 Fig). Note that endogenous Pfn1
expression was not affected by overexpression of any of these ectopic Pfn1 constructs (Fig 5C).
When we blocked new protein synthesis in HEK-293 cells by cycloheximide (CHX) treatment,
both WT- and T89A-variants of EGFP-Pfn1 showed no detectable change in the protein level
over a period of 8 hours but the expression level of T89D-Pfn1 declined substantially within 4
hours of CHX treatment (Fig 5E and 5F). These results demonstrate that T89D substitution
accelerates the protein turnover of Pfn1. Folding of proteins into alternative three-dimensional
conformation can lead to protein aggregation, insolubility and marking for proteolytic degra-
dation. As T89D-Pfn1 exhibits all of these hallmarks, it indirectly suggests that T89D substitu-
tion causes a significant conformational change in Pfn1, an interpretation that is consistent
with our in silico prediction of extreme destabilization of the intramolecular T89:F98 interac-
tion upon T89 phosphorylation. Therefore, T89 appears to be a structurally important residue
of Pfn1 that can be modified by phosphorylation.
Since a direct biochemical assessment of the effect of T89 phosphorylation on actin-bind-
ing of Pfn1 was not possible due to protein insolubility issues, we considered two indirect
approaches. First, we performed the standard pyrene-actin polymerization assay to deter-
mine whether PKA-mediated phosphorylation has any effect on Pfn1’s ability to inhibit actin
polymerization. In the absence of PKA, Pfn1 inhibited actin polymerization by ~30% when
added to actin at a 1:1 molar ratio. Unfortunately, pre-incubation with PKA (mimicking the
in vitro kinase assay condition) made little to no difference in the overall effect of Pfn1 on the
kinetics of actin polymerization (data not shown). This was not totally unexpected because if
only a very small fraction of Pfn1 is modified on T89 by PKA, the resulting effect would be
hard to detect in a bulk polymerization assay such as the pyrene-actin assay. It is possible
that PKA-mediated phosphorylation on other residues may have a confounding effect mask-
ing the effect of T89 phosphorylation.
Therefore, as an alternative strategy, we investigated the effect of constitutive T89 phosphor-
ylation of Pfn1 on actin polymerization in cells. First, we transiently overexpressed mCherry-
actin along with either WT- or T89A- or T89D- variants of Pfn1 (all constructs were EGFP-
fused) in MDA-MB-231 (MDA-231) breast cancer cells. As in HEK-293 cells, T89D-Pfn1 a)
expressed at a much lower level than either WT- or T89A-Pfn1 (Fig 6A), and b) formed promi-
nent aggregates (Fig 6B) in MDA-231 cells. Interestingly, mCherry-actin was also found to be
strikingly concentrated at T89D-Pfn1 clusters (Fig 6B). Clustering of mCherry-actin was not
observed in cells overexpressing either WT or T89A-Pfn1. We considered two scenarios by
which T89D-Pfn1 overexpression could induce actin clusters. One possibility is that T89D-
Pfn1 directly binds to actin and co-clusters actin at the sites of their aggregation. As there is
also experimental evidence of Pfn1’s ability to oligomerize at least in vitro [21], an alternative
possibility is that T89D-Pfn1 somehow oligomerizes with endogenous Pfn1 and in turn
recruits actin bound to endogenous Pfn1. To determine whether T89D-Pfn1:actin co-cluster-
ing requires the action of endogenous Pfn1, we re-assessed T89D-Pfn1:actin co-clustering in
cells expressing indicated EGFP-fused Pfn1 constructs show that EGFP-Pfn1-T89D causes clustering of this fusion
protein as indicated by the arrows. Scale bar represents 20 μm. E) HEK-293 cells expressing indicated EGFP-fused
Pfn1 constructs were treated with CHX for up to 8 hours. Cell lysates prepared at different time-points after CHX
addition were immunoblotted with the indicated antibodies. T89D-Pfn1 undergoes rapid protein degradation while WT-
and T89A-Pfn1 are stable over that period of time, similar to the characteristic of endogenous Pfn1 (degradation of
p27kip1, a cell-cycle protein that undergoes rapid turnover, validates CHX efficacy). Tubulin blot serves as the loading
control. F) The bar graph summarizes quantification of the time-dependent changes in the expression of the indicated
GFP-Pfn1 constructs following CHX treatment in HEK-293. Data was summarized from 3 independent experiments
(** indicates p < .01).
doi:10.1371/journal.pone.0156313.g005
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Fig 6. T89D-Pfn1 co-clusters with actin in cells. A) Lysates prepared fromMDA-231 cells expressing indicated EGFP-fused Pfn1 constructs were
immunoblotted with anti-GFP antibody to show the relative levels of various EGFP-Pfn1 constructs (tubulin blot serves as the loading control).B)
Fluorescence images of MDA-231 cells expressing indicated EGFP-fused Pfn1 and mCherry-actin demonstrate mCherry-actin clustering at the sites of
T89D-Pfn1 aggregates (arrows; Scale bar—20 μm).C) Fluorescence images of MDA-231 cells co-expressing mCherry-actin and EGFP-Pfn1-T89D, and
treated with Pfn1 siRNA reveal mCherry-actin:T89D-Pfn1 co-clusters (arrows; Scale bar—20 μm). Pfn1 immunoblot alongside confirms near complete
loss of endogenous Pfn1 expression in Pfn1-siRNA treated cells when compared against control siRNA transfected cells (tubulin blot—loading control).
doi:10.1371/journal.pone.0156313.g006
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MDA-231 cells when endogenous Pfn1 expression was selectively suppressed by siRNA trans-
fection. Even in a near complete absence of endogenous Pfn1 expression, prominent co-clus-
tering of mCherry actin and T89D-Pfn1 was observed (Fig 6C). These data suggest that in an
overexpression setting (i.e in the presence of endogenous Pfn1), co-clustering of mCherry-
actin and T89D-Pfn1 is most likely mediated by a direct interaction between T89D-Pfn1 and
actin rather than involving an indirect action of endogenous Pfn1. In parallel experiments, we
also found that overexpression of only T89D-Pfn1 but not WT- or T89A-Pfn1 has a significant
impact on the average level of polymerized actin (as measured by rhodamine-phalloidin fluo-
rescence on a cell-by-cell basis) in MDA-231 cells (Fig 7A and 7B; note that the overall expres-
sion of actin is not affected by T89D-Pfn1 overexpression (S3 Fig)). T89D-Pfn1 overexpression
resulted in a robust 60% decrease in average F-actin content/cell when compared to the GFP
control; there was no significant difference in average F-actin level between either of WT- or
T89A-Pfn1 overexpressor. Inhibitory action of T89D-Pfn1 on actin polymerization in cells,
taken together with the actin clustering ability of T89D-Pfn1 even in the absence of endoge-
nous Pfn1, is consistent with intact actin-binding of T89D-Pfn1 (or T89 phosphorylated Pfn1)
as predicted by MDS. Despite the low expression level of T89D-Pfn1 compared to either WT—
or T89A-Pfn1, a reduction in actin polymerization specifically in the setting of T89D-Pfn1
overexpression may suggest that T89D-Pfn1 has a dominant negative effect. This is clearly
possible if T89D-Pfn1 has a stronger affinity for the actin monomer than endogenous Pfn1
(as predicted by MDS) and is thereby able to competitively inhibit the endogenous Pfn1:actin
interaction.
T89 may be an in vivomodification site of Pfn1 in the basal state
We finally asked whether any subcellular pool of Pfn1 is post-translationally modified on T89
even under the basal condition. Unfortunately, we were unable to directly confirm T89
Fig 7. Overexpression of T89D-Pfn1 has a robust effect on actin cytoskeleton in MDA-231 cells. A) Fluorescence images of MDA-231 cells
expressing indicated EGFP-fused Pfn1 constructs and stained with rhodamine-phallodin staining. Scale bar represents 20 μm. B) A bar graph
summarizing the average rhodamine-phalloidin fluorescence intensity/cell for T89A-Pfn1 and T89D-Pfn1 expressors relative to that of WT-Pfn1
expressing and untransfected cells. ‘N’ indicates number of cells analyzed for each group pooled from 3 independent experiments (** indicates p < .01;
* indicates p < .05).
doi:10.1371/journal.pone.0156313.g007
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phosphorylation of Pfn1 by mass-spectrometry of immunoprecipitated myc-Pfn1 from HEK-
293 cells. We speculated that this could be either due to a) a possibility of only a very negligible
fraction of Pfn1 that is being modified at the T89 residue, and/or b) detergent insolubility of
T89-phosphorylated Pfn1 (as suggested by the biochemical characteristics of phosphomimetic
T89D-Pfn1) thus precluding T89-phosphorylated Pfn1 from the immunoprecipitated sample.
Therefore, we adopted an indirect approach where we expressed either WT- or non-phosphor-
ylatable T89A forms of Pfn1 as myc-tagged proteins in HEK-293 cells and analyzed their post-
translational modification patterns by two-dimensional gel electrophoresis (2D-GE). We rea-
soned that if any cellular pool of Pfn1 is phosphorylated on T89, rendering it non-phosphory-
latable should result in a basic charge shift of the isoelectric profile of Pfn1 in 2D GE. We
observed multiple charged states of myc-Pfn1 with the second spot representing the predomi-
nant pool of myc-Pfn1. Rendering T89 non-phosphorylatable by alanine substitution resulted
in basic shift of a small population of myc-Pfn1 (Fig 8). As spot #2 accounts for>95% of total
pool of myc-Pfn1, we used the relative intensities of spot #2 at a very low exposure (that does
not saturate the signal of this spot) between WT- and T89A-Pfn1 IEFs as a correction factor
for the loading control for the two groups. Using this correction factor, we estimated that
T89A substitution led to an approximately 8.9-fold (mean of two independent experiments)
increase in the ratio of intensity of spot #1 to that of spot #3 (a measure of net basic charge
shift). This finding is consistent with the scenario that a small fraction of cellular Pfn1 could be
post-translationally modified on the T89 residue in cells. Note that without direct mass-spec-
trometry-based evidence of T89 phosphorylation, we could not absolutely rule out an alterna-
tive interpretation that T89A substitution may render a certain pool of Pfn1 resistant to
phosphorylation or other types of post-translational modification on sites other than T89.
Discussion
It is well recognized that Pfn1 is a vital cog in the machinery that regulates actin polymerization
in cells. Therefore, how Pfn1’s interactions with actin and other major controllers of actin
Fig 8. Effect of non-phosphorylatable amino-acid substitution at T89 on post-translational
modification profile of Pfn1 in cells. 2D-GE of lysates from HEK-293 cells expressing either myc-Pfn1 or
myc-Pfn1-T89A demonstrate that alanine substitution at T89 results in a basic shift of a small portion of myc-
Pfn1.
doi:10.1371/journal.pone.0156313.g008
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polymerization are regulated is a fundamentally important biological question in the context of
actin-driven cellular events. There is emerging evidence that phosphorylation plays an impor-
tant role in tuning Pfn1’s ligand interactions. At present, only two phosphorylation events
(Y128, S137) have been directly linked to functional alterations of Pfn1. This study demon-
strates that Pfn1 can be directly phosphorylated by PKA, and accordingly, post-translationally
modified in a PKA-dependent manner in cells. We identified at least three PKA phosphoryla-
tion sites (S56/S57, T89, S91/T92). As phosphopeptides of Pfn1 involving all of these residues
were previously found in various proteomics screens [10,19,20], these phosphorylations appear
to be bona fide in vivo events. By MDS, we established similarities between the intramolecular
changes caused by actual T89 phosphorylation and T89D substitution suggesting T89D-Pfn1
reasonably mimics a T89-phosphorylated state of Pfn1. We further showed that T89D-Pfn1
exhibits hallmarks of proteins in an alternative three-dimensional conformation including pro-
tein aggregation when expressed in cells, insolubility and marking for proteolytic degradation.
Therefore, T89 appears to be a structurally critical residue of Pfn1 that is a target for phosphor-
ylation leading to significant biochemical consequence.
Previous studies have mutated residues near and adjacent to T89, including R88 and K90,
with no apparent impact on solubility [22,23]. Recently, several Pfn1 mutations (C71G,
M114T, E117G and G118V) have been linked to pathogenesis of familial Amyotrophic Lateral
Sclerosis (ALS) [24]. Except for E117G, the other three mutations were shown to result in pro-
tein aggregation and insolubility of Pfn1 in cells, very similar to the phenotypes exhibited by
phosphomimetic mutation of the T89 residue demonstrated in the present study. Another phe-
notypic parallel between the ALS-linked mutations and the T89D mutation was the inhibitory
effect on actin polymerization. ALS-linked mutations lie in close proximity to the actin-binding
residues of Pfn1 while the backbone of the T89 residue directly interacts with Y166 of actin. As
ALS-linked mutations still preserved a significant NP-40 soluble pool of Pfn1, a co-immuno-
precipitation assay was feasible in that study to demonstrate that ALS-linked mutations result
in reduced actin-binding of Pfn1. However, in our case, the insolubility issue of the T89D
mutant was much more severe, precluding us from performing similar biochemical assays. In
silico analyses predicted that phosphorylation of T89 could potentially result in an ‘actin-
friendly’ conformation because the backbone oxygen of T89 is more accessible to Y166 of actin
through destabilization of intramolecular T89:F98 interaction. T89D-Pfn1:actin co-clusters in
cells even in the near absence of endogenous Pfn1 expression is consistent with a direct interac-
tion of T89D-Pfn1 and actin, as predicted by the in silico analyses.
Is our in silico prediction of the increased strength of Pfn1:actin binding conferred by T89
phosphorylation consistent with reduced level of actin polymerization in cells upon T89D-Pfn1
overexpression? Pfn1 has dual effects on actin cytoskeleton. Pfn1 can either inhibit actin poly-
merization (by sequestering G-actin, inhibiting spontaneous or Arp2/3-mediated actin nucle-
ation) or promote barbed-end directed actin polymerization. Even for barbed-end elongation,
Pfn1 must also dissociate from G-actin following shuttling of G-actin to the barbed ends. If T89
phosphorylation dramatically enhances Pfn1’s affinity for actin to a point that dissociation of
the Pfn1:actin complex is greatly inhibited, in an overexpression setting T89D-Pfn1 should not
only competitively inhibit the endogenous Pfn1:actin interaction, but it could also act as a G-
actin sequestering protein resulting in an overall inhibition of actin polymerization. There is,
however, an alternative possibility that T89D-Pfn1 induces local actin polymerization at the
sites of its aggregation and in turn make less G-actin available for actin polymerization else-
where in the cell. We think this is unlikely since phalloidin staining did not reveal any F-actin
clusters at the sites of T89D-Pfn1 aggregates. Although it remains to be seen whether activating
the PKA pathway triggers T89 phosphorylation of Pfn1 in cells, if T89-phosphorylation of Pfn1
inhibits actin polymerization of Pfn1 as suggested by the F-actin phenotype of T89D-Pfn1
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expressors in this study, it would be at least consistent with the recent finding of FSK-induced
stellation of astrocytes in a Pfn-dependent manner [18].
Another interesting finding of this study was the faster protein turnover of Pfn1 conferred
by the phosphomimetic mutation on the T89 residue. Although the structural basis for this
observation is currently unclear, one simple explanation could be that T89D substitution
affects protein folding of Pfn1, and that the misfolded protein becomes a target for degradation.
Previous proteomic studies have found evidence of ubiquitination of the adjacent residue K90
[25,26]. Thus, it is possible that T89 phosphorylation induces a large structural change through
destabilizing the beta sheet structure which increases the accessibility of K90 (or other ubiqui-
tylable lysine residues) to ubiquitin-ligases and priming Pfn1 for degradation. If this is true,
T89 phosphorylation could be a triggering event for local protein turnover of Pfn1.
In conclusion, we have identified T89 phosphorylation as a novel post-translational modifi-
cation of Pfn1 which has important biochemical consequence on Pfn1. The actual biological
significance of T89 phosphorylation still needs to be resolved in future studies. Although phos-
phorylation of other PKA sites identified herein (S57, S91/T92) residues did not show any
obvious change in Pfn1’s ability to co-precipitate actin and PLP ligand in a GST-pull down
assay, without a quantitative binding assay, we cannot absolutely rule out subtle changes in
ligand affinity of Pfn1 due to these mutations. Furthermore, whether phosphorylation of any
these residues has any influence on other post-translational modifications or impacts other
functionalities of Pfn1 (such as PPI binding), particularly if they occur simultaneously, need
further investigation. Future studies should also examine whether PKA signaling influences
actin dynamics and actin-dependent biological processes such as cell migration through phos-
phorylation of Pfn1.
Supporting Information
S1 Fig. HEK-293 cells expressing myc-tagged T89D-Pfn1were lysed with either non-dena-
turing (containing 1% NP-40) or denaturing (containing 1% NP-40, 2% SDS for one buffer
and the other with 6M urea in addition) extraction buffers. Cell lysates were immunoblotted
with anti-myc antibody to demonstrate that myc-tagged T89D-Pfn1 is insoluble in non-dena-
turing lysis buffer.
(TIF)
S2 Fig. Quantitative RT-PCR shows comparable mRNA levels of all three GFP-tagged Pfn1
constructs in HEK-293 cells.
(TIF)
S3 Fig. Actin and tubulin (loading control) immunoblots of extracts prepared fromMDA-
231 cells expressing the indicated Pfn1 constructs as EGFP-tagged proteins.
(TIF)
S1 Table. Primer sequences used for site-directed mutagenesis of Pfn1.
(DOC)
S2 Table. Phosphorylation sites and associated kinases of human and mouse Pfn1, as pre-
dicted by NetphosK (threshold set at the default value of 0.5) and KinasePhos (prediction
accuracy set at 0.90). In addition to predicted sites that are annotated by the plus sign, this
table also includes a few kinase-specific experimentally validated phosphorylations, e.g. Src/
Y128, PKC/S137 and ROCK/S137, even though these did not meet the cut-off or prediction
accuracy criteria set in our analyses.
(TIF)
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